Crosslinked polymer, method for isolating a substance, kit for isolating a substance, kit for testing a disease, and device for isolating a substance
Crosslinked polymers with acidic groups and neutralizing bases enhance exosome separation by improving purity and reducing time, addressing inefficiencies in ultracentrifugation methods.
Patent Information
- Application Number
- JP2023511695
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-03-31
- Filing Date
- 2022-03-31
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2042-03-31
AI Technical Summary
Conventional size fractionation methods using ultracentrifuge for isolating exosomes are inefficient, resulting in impure samples and lengthy operations.
Development of crosslinked polymers containing monomer units with acidic groups and/or their neutralizing bases, which are used to separate substances with lipid bilayers such as exosomes by contacting a biological sample with the polymer, followed by mixing with a salt to recover the targeted substance.
The method improves the purity and reduces the operation time of exosome separation, offering higher reproducibility and efficiency compared to ultracentrifugation.
Smart Images

Figure 0007582633000001 
Figure 0007582633000002 
Figure 0007582633000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a crosslinked polymer and its uses. [Background technology]
[0002] Extracellular vesicles secreted from cells are endoplasmic reticulum surrounded by a lipid bilayer and containing proteins, nucleic acids, etc. inside, and function as intercellular information transmitters. Examples of extracellular vesicles include exosomes, microvesicles, and apoptotic bodies. Of these, exosomes (membrane vesicles with particle diameters of 30 to 100 nm) are secreted from various cells and their presence has been confirmed in all body fluids throughout the body, suggesting the possibility that they circulate in body fluids and transmit information to distant cells. Proteins, nucleic acids, etc. encapsulated in exosomes reflect the state of the cells that secreted them in real time, and are useful as biomarkers for evaluating the state of the original organism, intercellular information transmission, etc.
[0003] Size fractionation using an ultracentrifuge is a commonly used method for recovering exosomes from biological samples. This method uses a sucrose density gradient to separate relatively low-density exosomes from other particles. Summary of the Invention [Problem to be solved by the invention]
[0004] However, size fractionation using ultracentrifugation has problems such as the purity of the recovered exosomes being insufficient and the length of time required for the procedure.
[0005] An object of the present invention is to provide a crosslinked polymer that is useful for separating substances having a lipid bilayer, such as exosomes. [Means for solving the problem]
[0006] As a result of intensive research aimed at solving the above problems, the present inventors have found that a crosslinked polymer containing a monomer unit having an acidic group and / or a neutralizing base thereof, which contains a compound having at least one group selected from the group consisting of a cationic group and a hydroxyl group, is useful for separating a substance having a lipid bilayer, such as exosomes. The present invention was completed through further research based on this finding.
[0007] The present invention includes the following aspects. Section 1. A crosslinked polymer for separating a substance having a lipid bilayer from a biological sample, the crosslinked polymer comprising a monomer unit having an acidic group and / or a neutralizing base thereof, and containing a compound having at least one type of group selected from the group consisting of a cationic group and a hydroxyl group. Section 2. Item 2. The crosslinked polymer according to item 1, wherein the compound has an optionally substituted hydrocarbon group having 12 to 30 carbon atoms. Section 3. Item 3. The crosslinked polymer according to item 1 or 2, wherein the compound has a cationic group. Section 4. The cationic group is -N(R 1 )2(in the formula, each R 1 each independently represents a hydrogen atom or an optionally substituted hydrocarbon group having 1 to 6 carbon atoms), or -N + (R 2 )3(in the formula, each R 2 each independently represents a hydrogen atom or an optionally substituted hydrocarbon group having 1 to 6 carbon atoms. Section 5. Item 5. The crosslinked polymer according to any one of items 1 to 4, wherein the hydrocarbon group having 12 to 30 carbon atoms is an aliphatic hydrocarbon group having 12 to 20 carbon atoms or an alicyclic hydrocarbon group having 20 to 30 carbon atoms. Section 6. Item 6. The crosslinked polymer according to item 5, wherein the aliphatic hydrocarbon group is an alkyl group or an alkenyl group, and the alicyclic hydrocarbon group is a group having a steroid skeleton. Section 7. Item 7. The crosslinked polymer according to any one of items 1 to 6, wherein a physiological saline solution containing the crosslinked polymer at 0.5% by weight based on the weight of the physiological saline has a pH of 7 to 8. Section 8. 8. The crosslinked polymer according to any one of items 1 to 7, having a volume average particle size of 100 to 1000 μm. Section 9. Item 9. The crosslinked polymer according to any one of items 1 to 8, wherein the substance having a lipid bilayer is an extracellular vesicle. Section 10. A method for separating a substance having a lipid bilayer from a biological sample, comprising the following steps (1) and (2): (1) contacting a biological sample with the crosslinked polymer according to any one of claims 1 to 9 to obtain a polymer gel containing a substance having a lipid bilayer; and (2) mixing the polymer gel with a salt and recovering a material having a lipid bilayer; Section 11. Item 10. A kit for separating a substance having a lipid bilayer from a biological sample, the kit comprising the crosslinked polymer and salt according to any one of Items 1 to 9. Section 12. Item 10. A kit for testing a disease using extracellular vesicles, comprising the crosslinked polymer and salt according to any one of Items 1 to 9. Section 13. Item 11. An apparatus for separating a substance having a lipid bilayer from a biological sample, the apparatus comprising a means for carrying out the method according to item 10. Section 14. Item 10. Use of the crosslinked polymer according to any one of items 1 to 9 for separating a substance having a lipid bilayer from a biological sample. Effect of the Invention
[0008] The crosslinked polymer of the present invention can be suitably used for separating a substance having a lipid bilayer from a biological sample. The separation method of the present invention can increase the purity of the separated substance having a lipid bilayer and shorten the operation time, for example, compared with conventional ultracentrifugation methods. In addition, the separation method of the present invention can reduce the number of steps and has excellent reproducibility, compared with conventional ultracentrifugation methods. The separated substance having a lipid bilayer can be used for evaluating the state of the original organism (for example, testing or diagnosis). In addition, the separated substance having a lipid bilayer can be used as a carrier for cell-targeted therapeutic drugs, etc. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] (A) Crosslinked polymer The crosslinked polymers of the present invention contain monomer units having acidic groups and / or their neutralizing salt groups.
[0010] As used herein, the term "acidic group" refers to a group having a dissociable proton, and examples thereof include, but are not limited to, a carboxylic acid group (-COOH), a sulfonic acid group [-S(=O)2(OH)], a sulfate group [-OS(=O)2(OH)], a phosphonic acid group [-P(=O)(OH)2], and a phosphate group [-OP(=O)(OH)2].
[0011] In this specification, the term "neutralizing base of an acidic group" refers to a neutralizing base with any cation. Specific examples of the cation include metals (such as monovalent or divalent metals), cations of the formula: NR4 + (wherein each R independently represents a hydrogen atom or an optionally substituted hydrocarbon group, and two or three R may form a ring together with the adjacent nitrogen atom).
[0012] Examples of the monovalent metal include alkali metals such as lithium, sodium, potassium, etc. Examples of the divalent metal include alkaline earth metals such as magnesium, calcium, barium, etc., lead, zinc, tin, etc.
[0013] The formula: NR4 + In the cation represented by the formula (I), when R is a hydrocarbon group which may be substituted, the hydrocarbon group may be, for example, an alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group. Examples of the alkyl group include C groups such as a methyl group, an ethyl group, a propyl group (n-propyl group or isopropyl group), and a butyl group (n-butyl group, isobutyl group, sec-butyl group, or t-butyl group). 1-6 Examples of the cycloalkyl group include a C alkyl group such as a cyclopentyl group and a cyclohexyl group. 5-14 Examples of the aryl group include C aryl groups such as phenyl and naphthyl groups. 6-14 Examples of the aralkyl group include C aryl groups such as benzyl groups and phenethyl groups. 7-14 Examples include aralkyl groups.
[0014] Examples of the substituent that may be substituted on the hydrocarbon group include a halogen atom, a hydroxyl group, and a mercapto group.
[0015] The formula: NR4 + In the cation represented by the formula (I), when two or three R's form a ring together with the adjacent nitrogen atom, the ring may be a monocyclic ring such as a pyridine ring or an imidazole ring, or a condensed ring such as a quinoline ring. The ring may have one or more substituents, and examples of the substituents include a halogen atom, a hydroxyl group, an amino group, an alkyl group, a haloalkyl group, a hydroxyalkyl group, and an N,N-dialkylamino group. The number of the substituents is, for example, one, two, or three.
[0016] Representative examples of monomers having an acidic group include unsaturated carboxylic acids. Unsaturated carboxylic acids include, for example, unsaturated monocarboxylic acids and unsaturated dicarboxylic acids. Examples of unsaturated monocarboxylic acids include unsaturated monocarboxylic acids having 3 to 10 carbon atoms, such as acrylic acid, methacrylic acid, and crotonic acid. Examples of unsaturated dicarboxylic acids (including anhydrides in this specification) include unsaturated dicarboxylic acids having 4 to 10 carbon atoms, such as maleic acid, fumaric acid, citraconic acid, and itaconic acid, and anhydrides thereof.
[0017] Examples of monomers having other acidic groups include (meth)acrylic monomers having a sulfonic acid group [e.g., (meth)acrylic acid sulfoalkyl esters such as 2-sulfoethyl (meth)acrylate, and N-sulfoalkyl (meth)acrylic acid amides such as 2-(meth)acrylamido-2-methylpropanesulfonic acid], and (meth)acrylic monomers having a phosphoric acid group [e.g., (meth)acrylic acid phosphonooxyalkyl esters such as 2-((meth)acryloyloxy)ethyl phosphoric acid]. In this specification, (meth)acrylic means acryl and / or methacryl, and (meth)acryloyloxy means acryloyloxy and / or methacryloyloxy.
[0018] The monomer having an acidic group may be used alone or in combination of two or more kinds.
[0019] Representative examples of the monomer having a neutralizing base of an acidic group include unsaturated carboxylate.Examples of unsaturated carboxylate include alkali metal salts (e.g., sodium salt, potassium salt), alkylamine salts (e.g., trialkylamine salts such as triethylamine salt), alkanolamine salts (e.g., dialkanolamine salts such as diethanolamine salt, trialkanolamine salts such as triethanolamine salt), ammonium salts, or tetraalkylammonium salts (e.g., tetramethylammonium salt, tetraethylammonium salt) of unsaturated carboxylic acid.
[0020] Examples of monomers having a neutralized base of other acidic groups include neutralized salts of the above-mentioned (meth)acrylic monomers having a sulfonic acid group, neutralized salts of the above-mentioned (meth)acrylic monomers having a phosphoric acid group, etc. Examples of these neutralized salts include the above-mentioned alkali metal salts, etc.
[0021] The monomer having a neutralized salt group of an acidic group may be used alone or in combination of two or more kinds.
[0022] The crosslinked polymer of the present invention preferably contains both a monomer unit having an acidic group and a monomer unit having a neutralized base of the acidic group. That is, in the crosslinked polymer containing a monomer unit having an acidic group, a part of the monomer unit having an acidic group is preferably neutralized and replaced with a monomer unit having a neutralized base of the acidic group. The degree of neutralization [100 x (molar number of neutralized bases of acidic groups) / (total mole number of acidic groups and their neutralized bases)] is not particularly limited, but may be, for example, 25 mol% or more, 30 mol% or more, 35 mol% or more, 40 mol% or more, 45 mol% or more, or 50 mol% or more, or 90 mol% or less, 85 mol% or less, or 80 mol% or less.
[0023] The crosslinked polymer of the present invention may further contain other monomer units in addition to the monomer units having an acidic group and / or a neutral salt thereof. Examples of the other monomers include the following monofunctional ethylenically unsaturated monomers. Esters of unsaturated carboxylic acids (e.g., acrylic acid, methacrylic acid, etc.) (e.g., alkyl esters such as methyl ester, ethyl ester, propyl ester, butyl ester, pentyl ester, hexyl ester, heptyl ester, octyl ester, 2-ethylhexyl ester, etc.; hydroxyalkyl esters such as 2-hydroxyethyl ester; haloalkyl esters such as 2,2,2-trifluoroethyl ester; aminoalkyl esters such as 2-aminoethyl ester; (mono- or dialkylamino)alkyl esters such as 2-(N,N-dimethylamino)ethyl ester; cycloalkyl esters such as cyclohexyl ester; aryl esters such as phenyl ester and naphthyl ester; aralkyl esters such as benzyl ester and phenethyl ester; glycidyl esters; polyethylene glycol esters, etc.) Unsaturated carboxylic acid amides (e.g., free amides; N-substituted amides such as N-monoalkylamides and N,N-dialkylamides) Unsaturated dicarboxylic acid imides (e.g., maleimide, citraconimide, itaconimide, their N-alkyl substituted, N-cycloalkyl substituted, or N-aryl substituted derivatives, etc.) Alkenyl esters (e.g., vinyl esters, allyl esters, etc.) of saturated carboxylic acids (e.g., acetic acid, propionic acid, etc.) Esters or amides of unsaturated sulfonic acids (for example, esters or amides of unsaturated sulfonic acids corresponding to the esters or amides of unsaturated carboxylic acids exemplified above) · Unsaturated alcohols (e.g., allyl alcohol, propenyl alcohol, etc.) Unsaturated ethers (e.g., alkyl vinyl ethers such as methyl vinyl ether and ethyl vinyl ether; alkyl allyl ethers such as methyl allyl ether and ethyl allyl ether; cycloalkyl vinyl ethers such as cyclohexyl vinyl ether; glycidyl vinyl ether, etc.) ·Unsaturated nitriles (e.g., acrylonitrile, methacrylonitrile, etc.) Olefins (e.g., ethylene, propylene, butene, pentene, hexene, etc.) Aromatic vinyl compounds (e.g., styrene, α-methylstyrene, vinyltoluene, hydroxystyrene, etc.) Heterocyclic vinyl compounds (e.g., N-vinylpyrrolidone, etc.) The other monomers may be used alone or in combination of two or more kinds.
[0024] The monomer constituting the crosslinked polymer preferably has a solubility in water (g / 100 g water) of 1 g or more, more preferably 5 g or more, at 25° C. The monomer constituting the crosslinked polymer may be miscible with water.
[0025] The crosslinked polymer of the present invention is a polymer having a crosslinked structure [a structure in which the constituent atoms of a plurality of linear macromolecules (polymers of monomers having acidic groups and / or their neutralizing bases) are covalently bonded to each other directly or via other atoms]. When the monomers constituting the crosslinked polymer have reactive groups (for example, a monomer having a carboxyl group and a monomer having an amino group are used in combination), the crosslinked structure may be self-crosslinked, or may be crosslinked with any crosslinking agent as necessary.
[0026] Examples of the crosslinking method using a crosslinking agent include the following methods. 1) A method using the following internal crosslinking agent: The above-mentioned monomer and the internal crosslinking agent are polymerized to directly obtain a crosslinked polymer having a crosslinked structure [for example, the methods described in JP-A-2003-225565 and JP-A-2005-075982] 2) A method using the following surface crosslinking agent: A polymer containing the above-mentioned monomer as an essential constituent monomer is crosslinked using a surface crosslinking agent to obtain a crosslinked polymer [for example, the methods described in Japanese Patent No. 3648553, JP-A No. 2003-165883, JP-A No. 2003-225565, JP-A No. 2005-75982, and JP-A No. 2005-95759, etc.]
[0027] The crosslinking agent (including an internal crosslinking agent and a surface crosslinking agent) is not particularly limited, but examples thereof include the following difunctional or higher ethylenically unsaturated monomers. Alkenyl ethers (e.g., vinyl ethers, allyl ethers, etc.) of dihydric or higher alcohols (e.g., alkylene glycols or polyalkylene glycols (the alkylene group preferably has 2 to 4 carbon atoms, and the alkylene oxide preferably has 10 to 50 repeating numbers) such as ethylene glycol, polyethylene glycol, propylene glycol, butylene glycol, and neopentyl glycol, glycerin, polyglycerin, trimethylolethane, trimethylolpropane, pentaerythritol, dipentaerythritol, and sorbitan) Esters of unsaturated carboxylic acids (e.g., acrylic acid, methacrylic acid, etc.) and dihydric or higher alcohols (e.g., those exemplified as ethers above) · Alkenyl esters (e.g., vinyl esters, allyl esters, etc.) of unsaturated carboxylic acids (e.g., acrylic acid, methacrylic acid, etc.) Alkenyl esters (e.g., vinyl esters, allyl esters, etc.) of polycarboxylic acids (e.g., tartaric acid, citric acid, adipic acid, etc.) Alkenyl esters of isocyanuric acid (e.g., triallyl isocyanate) Alkylenebisacrylamide (e.g., methylenebisacrylamide, etc.) Alkylene bismethacrylamides (e.g., methylene bismethacrylamide, etc.) Di- or trialkenylamines (e.g., diallylamine, triallylamine, etc.) Aromatic polyvinyl compounds (e.g., divinylbenzene, etc.)
[0028] The crosslinking agent may have at least two functional groups capable of reacting with the substituents (such as a carboxyl group, a hydroxyl group, etc.) of the monomer. Examples of such crosslinking agents include polyhydric alcohol glycidyl ethers (e.g., alkylene glycol diglycidyl ethers such as ethylene glycol diglycidyl ether, and alkane triol di- or triglycidyl ethers such as glycerin diglycidyl ether).
[0029] The crosslinking agent may be used alone or in combination of two or more kinds.
[0030] The amount of the crosslinking agent can be appropriately selected depending on the desired crosslinking density, and may be, for example, 0.005 mol % or more, or 0.01 mol % or more, or 0.5 mol % or less, or 0.4 mol % or less, relative to the monomers constituting the crosslinked polymer.
[0031] The crosslinked polymer of the present invention contains (or carries) a compound having at least one group selected from the group consisting of a cationic group and a hydroxyl group (hereinafter referred to as "compound X"). That is, the crosslinked polymer of the present invention has the form of a coexisting substance with compound X. It is preferable that compound X is present on the surface of the crosslinked polymer of the present invention, and it is preferable that compound X is attached or fixed to the surface of the crosslinked polymer of the present invention by a non-covalent bond such as a hydrogen bond or an ionic bond, and it is preferable that a part or the whole of the surface of the crosslinked polymer of the present invention is covered with compound X. The surface of the crosslinked polymer means the molecular chain of the crosslinked polymer, or, when the crosslinked polymer is in the form of particles or pellets, the surface of the particles or pellets of the crosslinked polymer.
[0032] The presence of compound X in the crosslinked polymer of the present invention can be identified, for example, by immersing the crosslinked polymer in an appropriate solvent (e.g., a hydrocarbon solvent such as hexane), liberating compound X in the solvent, isolating compound X, and subjecting it to NMR and gas chromatography.
[0033] Compound X preferably has at least one group selected from the group consisting of cationic groups and hydroxyl groups, and a hydrocarbon group having 2 to 30 carbon atoms which may be substituted, more preferably has at least one group selected from the group consisting of cationic groups and hydroxyl groups, and a hydrocarbon group having 12 to 30 carbon atoms which may be substituted, and more preferably has a hydrocarbon group having 12 to 30 carbon atoms which may be substituted at one end, and at least one group selected from the group consisting of cationic groups and hydroxyl groups at the other end. In compound X, the number of the hydrocarbon group, cationic group, or hydroxyl group may be one or more. In this specification, compound X is said to have a cationic group and a hydroxyl group when compound X has a hydrocarbon group having 2 to 30 carbon atoms (or 12 to 30 carbon atoms) which may be substituted, and the hydrocarbon group contains a hydroxyl group as a substituent, also.
[0034] The hydrocarbon group having 12 to 30 carbon atoms may be any of aliphatic hydrocarbon groups such as alkyl groups and alkenyl groups, alicyclic hydrocarbon groups such as cycloalkyl groups and cycloalkenyl groups, and aromatic hydrocarbon groups. Examples of the substituent of the hydrocarbon group include a hydroxyl group, an oxo group (=O), an alkoxy group, an alkenyloxy group, and combinations thereof. The number of the substituent of the hydrocarbon group is, for example, 1, 2, 3, 4, or 5.
[0035] The aliphatic hydrocarbon group having 12 to 30 carbon atoms may be either saturated or unsaturated, and examples thereof include aliphatic hydrocarbon groups having 12 to 20 carbon atoms, such as a lauryl group, a myristyl group, a palmityl group, a stearyl group, an oleyl group, a linoleyl group, and an arachidyl group.
[0036] For example, lecithin contains, as an optionally substituted aliphatic hydrocarbon group having 12 to 30 carbon atoms, C 12-30Lecithin has an acyl group, specifically, an oleyloxy group and a palmitoyloxy group, and more specifically, has a diacylglycerol skeleton having the acyl group.
[0037] Examples of the alicyclic hydrocarbon group having 12 to 30 carbon atoms include groups having a steroid skeleton. The steroid skeleton is, for example, represented by the following formula (1): [ka] (In the formula, the dashed line of ring A indicates that any carbon-carbon single bond may be a carbon-carbon double bond, the dashed line of ring B indicates that the carbon-carbon single bond may be a carbon-carbon double bond, and rings A to D may each be substituted. Note that the numbers on the rings are written for the sake of convenience to indicate the substitution positions of the substituents.)
[0038] Examples of the substituents that can be substituted on rings A to D include a hydroxyl group, an oxo group (=O), an alkyl group (e.g., an alkyl group having 1 to 4 carbon atoms such as a methyl group), a combination thereof (e.g., a hydroxyalkyl group), etc. The substitution position of the substituent is not particularly limited, and examples thereof include the 3rd, 7th, 10th, 11th, 12th, 13th, and 17th positions.
[0039] The skeleton represented by formula (1) includes skeletons represented by the following formulae (1-1) to (1-5): [ka]
[0040] The alicyclic hydrocarbon group having 12 to 30 carbon atoms is Preferably, it is an alicyclic hydrocarbon group having 20 to 30 carbon atoms. More preferably, it is a group in which an optionally substituted alkylene group (for example, an alkylene group having 2 to 4 carbon atoms such as an ethylene group or a propylene group) is linked to the 17-position of the skeleton represented by formula (1), More preferably, it is a group in which an optionally substituted alkylene group (for example, an alkylene group having 2 to 4 carbon atoms such as an ethylene group or a propylene group) is linked to the 17-position of a skeleton represented by any one of formulas (1-1) to (1-5).
[0041] Examples of aromatic hydrocarbon groups having 12 to 30 carbon atoms include fluorene, anthracene, phenanthrene, tetracene, pyrene, triphenylene, chrysene, and tetraphenylene.
[0042] The optionally substituted hydrocarbon group having 12 to 30 carbon atoms is diC 12-30 A group having an acylglycerol skeleton or a group having a steroid skeleton is preferred.
[0043] In the present specification, the term "cationic group" includes a group that itself forms a cation, and a group that does not itself form a cation but can form a cation by bonding with a proton. Examples of cationic groups include -N(R 1 )2(in the formula, each R 1 each independently represents a hydrogen atom or an optionally substituted hydrocarbon group having 1 to 6 carbon atoms), -N + (R 2 )3(in the formula, each R 2 each independently represents a hydrogen atom or an optionally substituted hydrocarbon group having 1 to 6 carbon atoms).
[0044] R in the above formula 1 and R 2 In the above formula, examples of the hydrocarbon group having 1 to 6 carbon atoms include alkyl groups such as a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, and a hexyl group. Examples of the substituent that may be substituted on the hydrocarbon group having 1 to 6 carbon atoms include a hydroxyl group, an oxo group, a carboxylic acid group, and a sulfonic acid group.
[0045] The formula: -N(R 1 The group represented by -NH or -N(R 11 )2(wherein, R11 represents a hydroxyalkyl group having 1 to 5 carbon atoms. Examples of the hydroxyalkyl group having 1 to 5 carbon atoms include a hydroxyethyl group, a hydroxypropyl group, a hydroxybutyl group, and a hydroxypentyl group (including a pentahydroxypentyl group).
[0046] The formula: -N + (R 2 The group represented by 3 is preferably -N + (CH3)3, -N + (CH3)2(C2H5), -N + (CH3)2(C3H7), and these groups are, for example, -CO2 - , -SO3 - and the like.
[0047] Preferable examples of compound X include compounds having an aliphatic hydrocarbon group having 12 to 30 carbon atoms and a cationic group (e.g., lecithin, hexadecyltrimethylammonium chloride), compounds having a hydrocarbon group having 12 to 30 carbon atoms and a hydroxyl group (e.g., lauryl alcohol, BIGCHAP), compounds having an alicyclic hydrocarbon group having 12 to 30 carbon atoms, a cationic group, and a hydroxyl group (e.g., CHAPS), compounds having a cationic group and a hydroxyl group (e.g., triethanolamine), polymers having a cationic group (e.g., polylysine, polyethyleneimine), and the like.
[0048] The lower limit of the molar concentration of the cationic group per mole of compound X (particularly when compound X is a polymer having a cationic group) is preferably 1 mole or more, and from the viewpoint of improving the recovery amount of the substance having a lipid bilayer, it is preferably 5 moles or more, and more preferably 10 moles or more. In addition, the upper limit of the molar concentration of the cationic group per mole of compound X is preferably 100 moles or less.
[0049] From the perspective of improving the recovery amount of the substance having a lipid bilayer, the lower limit of the chemical formula weight or the number average molecular weight of Compound X is preferably 300 or more, and more preferably 500 or more. The upper limit of the chemical formula weight or the number average molecular weight of Compound X is preferably 10,000 or less. Note that the number average molecular weight of Compound X can be measured under the following conditions using gel permeation chromatography (GPC). <GPC measurement conditions> [1] Apparatus: Gel permeation chromatography [Model number "HLC-8120GPC", manufactured by Tosoh Corporation] [2] Column: "TSKgel G6000PWxl", "TSKgel" G3000PWxl" [both manufactured by Tosoh Corporation] in series connected. [3] Eluent: Methanol / water = 30 / 70 (volume ratio) with 0.5 wt% sodium acetate dissolved therein. [4] Standard substance: Polyethylene glycol (hereinafter abbreviated as PEG) [5] Injection conditions: Sample concentration 0.25 wt%, column temperature 40 °C
[0050] The crosslinking agent polymer of the present invention is preferably particles having a volume average particle diameter in the range of 50 μm or more, 60 μm or more, 70 μm or more, 80 μm or more, 90 μm or more, 100 μm or more, 110 μm or more, 120 μm or more, 130 μm or more, 140 μm or more, or 150 μm or more in terms of reducing impurities (such as albumin) in the separation of the substance having a lipid bilayer. Also, from the perspective of improving the recovery amount of the substance having a lipid bilayer, the crosslinking agent polymer of the present invention is preferably particles having a volume average particle diameter in the range of 2000 μm or less, 1500 μm or less, 1000 μm or less, 500 μm or less, or 300 μm or less. The volume average particle diameter can be measured by the method described in the examples below.
[0051] The pH of a physiological saline solution containing 0.5% by weight of the crosslinked polymer of the present invention based on the weight of the physiological saline (hereinafter abbreviated as "physiological saline solution pH") is not particularly limited. In order to reduce negatively charged impurities (such as albumin) in the separation of a substance having a lipid bilayer from a biological sample, the physiological saline solution pH is preferably 6.5 or more, 7 or more, or 7.2 or more, and is preferably 8.5 or less, 8 or less, 7.9 or less, or 7.5 or less. The physiological saline solution pH can be measured by the method described in the Examples below.
[0052] The pH of the saline solution can be adjusted by the degree of neutralization; if the pH of the saline solution is too low, increasing the degree of neutralization will tend to increase the pH of the saline solution; if the pH of the saline solution is too high, decreasing the degree of neutralization will tend to decrease the pH of the saline solution.
[0053] From the viewpoint of improving the recovery amount of a substance having a lipid bilayer, the water absorption capacity of the crosslinked polymer of the present invention in physiological saline (absorption capacity of physiological saline) is preferably 1 g / g or more, more preferably 3 g / g or more, particularly preferably 5 g / g or more, particularly preferably 10 g / g or more, and most preferably 15 g / g or more. When the water absorption capacity of the crosslinked polymer of the present invention in physiological saline (absorption capacity of physiological saline) is too low, the capacity tends to increase by increasing the amount of the crosslinking agent. The upper limit of the water absorption capacity of the crosslinked polymer of the present invention in physiological saline (absorption capacity of physiological saline) is not particularly limited, but is preferably 120 g / g or less, more preferably 100 g / g or less, and particularly preferably 50 g / g or less. The absorption capacity of physiological saline can be measured by the method described in the Examples below.
[0054] When the crosslinked polymer of the present invention has a cationic group, the molar concentration of the cationic group is preferably 6×10 based on the weight of the crosslinked polymer after drying, from the viewpoint of improving the recovery amount of the substance having a lipid bilayer. -6 ~1×10 -4It is preferably expressed in mol / g. The weight of the crosslinked polymer after drying can be measured, for example, by the following method. 1 g of the crosslinked polymer is placed on a petri dish, covered with filter paper, and heated and dried at 130° C. for 60 minutes in a circulating air dryer, and the weight of the residue thereafter can be regarded as the weight of the crosslinked polymer after drying.
[0055] Since the compound X contained in the crosslinked polymer of the present invention has excellent affinity with a substance having a lipid bilayer, the crosslinked polymer of the present invention can be suitably used for separating a substance having a lipid bilayer from a biological sample. Examples of the substance having a lipid bilayer include extracellular vesicles such as exosomes.
[0056] The crosslinked polymer of the present invention can be produced, for example, by a method including a step of polymerizing (solution polymerization, emulsion polymerization, suspension polymerization, etc.) a composition containing a monomer, a crosslinking agent, a solvent, an initiator, and, if necessary, a neutralizing agent, a step of drying the polymerized product, and, if necessary, a step of classifying the polymerized product.
[0057] (B) A method for isolating a substance having a lipid bilayer from a biological sample The method for separating a substance having a lipid bilayer from a biological sample includes the following steps (1) and (2): (1) contacting a biological sample with a crosslinked polymer to obtain a polymer gel containing a substance having a lipid bilayer; and (2) mixing the polymer gel with a salt and recovering a material having a lipid bilayer;
[0058] The biological sample used in step (1) is not particularly limited as long as it contains a substance having a lipid bilayer. Examples of biological samples include human or animal body fluids such as blood, plasma, serum, tears, saliva, breast milk, pleural fluid, peritoneal fluid, amniotic fluid, cerebrospinal fluid, and urine; liquefied tissues or cells such as organs, hair, nails, skin, muscle, and nerves (including cell culture fluid and its supernatant); and extracts from plants. The biological sample may be one type alone or a combination of two or more types. The biological sample is preferably a body fluid, and more preferably blood, plasma, serum, or urine.
[0059] The crosslinked polymer used in step (1) may be the same as that described in the above "(A) Crosslinked Polymer". The amount of the crosslinked polymer used is, for example, preferably 1 part by mass or more, 5 parts by mass or more, or 10 parts by mass or more, and preferably 2000 parts by mass or less, 1500 parts by mass or less, or 1000 parts by mass or less, per 100 parts by mass of the biological sample.
[0060] The temperature at which the crosslinked polymer is brought into contact with the biological sample is, for example, within the range of 1 to 35° C., and preferably within the range of 5 to 30° C. After the contact, it is preferable to leave the sample to stand for a predetermined time (for example, 1 hour or more, or 2 hours or more, or 5 hours or less, or 4 hours or less).
[0061] By step (1), a substance having a lipid bilayer can be separated into a polymer gel.
[0062] The salt used in step (2) is not particularly limited as long as it can discharge the substance having a lipid bilayer contained in the polymer gel. Examples of the salt include metal salts (such as monovalent or divalent metal salts).
[0063] Examples of the monovalent metal salt include alkali metal salts such as sodium salts and potassium salts, etc. Examples of the divalent metal salt include alkaline earth metal salts such as magnesium salts, calcium salts and barium salts.
[0064] Examples of counter anions of the salt include, but are not limited to, halide ions such as chloride ion and bromide ion.
[0065] The salt may be one type alone or a combination of two or more types. The salt is preferably at least one type selected from the group consisting of sodium chloride and magnesium chloride.
[0066] The amount of salt used can be, for example, 1 part by mass or more, 5 parts by mass or more, or 10 parts by mass or more, and can be 2000 parts by mass or less, 1500 parts by mass or less, or 1000 parts by mass or less, per 100 parts by mass of polymer gel.
[0067] The temperature for mixing the polymer gel and the salt is preferably within the range of, for example, 1 to 35° C., or within the range of 5 to 30° C. After mixing, it is preferable to leave the mixture to stand for a predetermined time (for example, 1 hour or more, 2 hours or more, or 5 hours or less, or 4 hours or less). The mixture of the polymer gel and the salt may be dialyzed as necessary.
[0068] By the step (2), a substance having a lipid bilayer contained in the polymer gel can be recovered with a high recovery rate. Examples of the substance having a lipid bilayer to be recovered include extracellular vesicles such as exosomes.
[0069] The method of the present invention can increase the purity of the recovered lipid bilayer-containing material (reduce the amount of contaminants) and shorten the operation time, compared to conventional ultracentrifugation methods.
[0070] (C) A kit for isolating a substance having a lipid bilayer from a biological sample. The present invention encompasses a kit for separating a substance having a lipid bilayer from a biological sample, the kit including a crosslinked polymer and a salt. The configuration of the kit preferably corresponds to the above-mentioned "(B) Method for separating a substance having a lipid bilayer from a biological sample." The kit of the present invention may further include an instruction manual including an explanation regarding the method for separating a substance having a lipid bilayer from a biological sample, an instrument for the separation, and the like.
[0071] (D) Kit for testing for diseases using extracellular vesicles The present invention includes a kit for testing (or diagnosing) a disease using extracellular vesicles, the kit comprising a crosslinked polymer and a salt.
[0072] The test subjects may be either healthy individuals or patients with diseases, such as lifestyle-related diseases, chronic kidney disease, neurological diseases, immune diseases, cancer, infectious diseases, and degenerative diseases.
[0073] The kit may be, for example, a kit for separating extracellular vesicles from a sample derived from a test subject (e.g., body fluids such as blood, plasma, serum, tears, saliva, breast milk, pleural fluid, peritoneal fluid, amniotic fluid, cerebrospinal fluid, and urine) and testing for a disease based on the contents of the extracellular vesicles. The kit may be a kit that contains a crosslinked polymer and a salt as a reagent for separating extracellular vesicles from a sample derived from a test subject in a known kit for testing for a disease using extracellular vesicles.
[0074] The crosslinked polymer and salt in the kit may be the same as those described in "(B) Method for separating a substance having a lipid bilayer from a biological sample". The kit may further include an instruction manual including an explanation on a method for separating extracellular vesicles from a test subject, an instrument for the separation, and the like.
[0075] (E) Apparatus for separating a substance having a lipid bilayer from a biological sample The present invention includes an apparatus for separating a substance having a lipid bilayer from a biological sample, the apparatus comprising a means for carrying out the above-mentioned "(B) Method for separating a substance having a lipid bilayer from a biological sample." EXAMPLES
[0076] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these.
[0077] <Saline solution pH measurement method> In a cylindrical 100 mL beaker with a diameter of 50 mm, 0.5 g of the measurement sample was mixed with physiological saline (salt concentration 0.9 wt%) to make the total amount 100 g, and the mixture was stirred at 60 rpm for 30 minutes at 25° C. with a stirrer tip (length 30 mm) and then allowed to stand for 1 minute at 25° C. After standing, the pH of the supernatant at 25° C. was measured with a pH meter, and the value was taken as the pH of the physiological saline solution.
[0078] <Method for measuring the absorption rate of saline solution> 1 g of the measurement sample was placed in a tea bag (20 cm long, 10 cm wide) made of nylon net with an opening of 63 μm (JIS Z8801-1:2006), and immersed in 1000 ml of physiological saline (salt concentration 0.9% by weight) for 1 hour without stirring, then hung for 15 minutes to drain. The weight of the tea bag (h1) was then measured, and the absorption rate of physiological saline was calculated using the following formula. Absorption rate of saline solution (g / g) = (h1) - (h2) The temperature of the physiological saline solution and the measurement atmosphere was 25° C.±2° C. The weight of the tea bag was measured (h2) in the same manner as above, except that no measurement sample was used.
[0079] <Production Example 1: Production of Crosslinked Polymer (A-1)> 116.5g of acrylic acid, 272.2g of ion-exchanged water, and 1.5g of ethylene glycol diglycidyl ether (1.3% by weight / acrylic acid) as a crosslinking agent were mixed in a 1-liter beaker to dissolve the crosslinking agent. While cooling the beaker in an ice bath, 96.1g of 48.5% by weight aqueous sodium hydroxide solution was added to neutralize a portion of the acrylic acid (72 mol%). After cooling the neutralized monomer solution to 5°C, 9.3g of 2% by weight aqueous potassium persulfate solution was added as a polymerization initiator to obtain an aqueous monomer solution. Into a 2-liter separable flask equipped with a stirrer and a condenser (cooler), 1,434 g of cyclohexane and 7.1 g of Rheodor SP-S10V (Kao Corporation, sorbitan monostearate) as a dispersant were placed, and the mixture was heated to an internal temperature of 60°C using a hot water bath and stirred to dissolve the dispersant in the cyclohexane. After nitrogen was passed through the solution in the separable flask to reduce the dissolved oxygen in cyclohexane to 0.1 ppm or less, 350 g of the monomer aqueous solution was dropped using a dropping funnel while stirring with a stirrer, and reverse phase suspension polymerization was performed at a polymerization temperature of 80 ° C. After the end of the dropwise addition of the monomer aqueous solution, the mixture was heated for another 2 hours to complete the suspension polymerization, and a spherical hydrogel was obtained in cyclohexane. The rotation of the stirrer was stopped, and the hydrogel formed was allowed to settle, after which cyclohexane was removed by decantation, and the remaining hydrogel was washed several times with cyclohexane to remove the dispersant adhering to the hydrogel. The obtained spherical hydrogel was spread on a release paper and dried for 1 hour in a vacuum dryer at 130 ° C. (vacuum pressure: 10,000 to 20,000 Pa) to obtain a crosslinked polymer (X-1). This crosslinked polymer (X-1) was adjusted to have a particle size of 150 to 300 μm using sieves with openings of 150 and 300 μm, thereby obtaining a crosslinked polymer (A-1). The volume average particle size of the crosslinked polymer (A-1) was measured with a particle analyzer (CAMSIZER XT, manufactured by Retsch) and found to be 220 μm. The absorption capacity of physiological saline was 26 g / g.
[0080] <Production Example 2: Production of Crosslinked Polymer (A-2)> A crosslinked polymer (X-2) was obtained in the same manner as in the production method for the crosslinked polymer (X-1) in Production Example 1, except that the amount of ethylene glycol diglycidyl ether was 3.0 g (2.6 wt % / acrylic acid). This crosslinked polymer (X-2) was adjusted to have a particle size of 150 to 300 μm using sieves with openings of 150 and 300 μm, thereby obtaining a crosslinked polymer (A-2). The volume average particle size of the crosslinked polymer (A-2) was measured with a particle analyzer (CAMSIZER XT, manufactured by Retsch) and found to be 200 μm. The absorption capacity of physiological saline was 16 g / g.
[0081] <Production Example 3: Production of Crosslinked Polymer (A-3)> A crosslinked polymer (X-3) was obtained in the same manner as in the production method for the crosslinked polymer (X-1) in Production Example 1, except that the amount of ethylene glycol diglycidyl ether was changed to 0.58 g (0.5 wt % / acrylic acid). This crosslinked polymer (X-3) was adjusted to have a particle size of 300 to 500 μm using sieves with openings of 300 and 500 μm, thereby obtaining a crosslinked polymer (A-3). The volume average particle size of the crosslinked polymer (A-3) was measured with a particle analyzer (CAMSIZER XT, manufactured by Retsch) and found to be 410 μm. The absorption capacity of physiological saline was 35 g / g.
[0082] <Production Example 4: Production of Crosslinked Polymer (A-4)> 300 g of acrylic acid, 700 g of ion-exchanged water, and 2.0 g of trimethylolpropane triacrylate (0.66 wt % / acrylic acid) as a crosslinking agent were placed in a 2-liter beaker and mixed with stirring to prepare an aqueous acrylic acid solution, which was then cooled to 3°C. The acrylic acid aqueous solution was placed in a 2-liter adiabatic polymerization tank, and nitrogen was passed through the acrylic acid aqueous solution to reduce the amount of dissolved oxygen in the acrylic acid aqueous solution to 0.1 ppm or less. 1.2 g of a 1 wt% aqueous hydrogen peroxide solution, 2.3 g of a 2 wt% aqueous L-ascorbic acid solution, and 4.5 g of a 2 wt% aqueous 2,2'-azobis[2-methyl-N-(2-hydroxyethyl)-propionamide] solution (manufactured by Wako Pure Chemical Industries, Ltd., product name: VA-086) were added to this adiabatic polymerization tank, and nitrogen was continued to be passed through the acrylic acid aqueous solution until polymerization began. After it was confirmed that polymerization had begun and the viscosity of the acrylic acid aqueous solution had begun to increase, nitrogen was stopped and polymerization was continued for 6 hours. The temperature of the acrylic acid aqueous solution was measured with a dot thermometer, and the maximum temperature reached was 94°C. The block-shaped crosslinked hydrogel was removed from the insulated polymerization tank and chopped into noodles with a small meat chopper (manufactured by Royal Co., Ltd.) with a thickness of 3 to 10 mm. The hydrogel was then neutralized by adding 292 g of a 40 wt % aqueous solution of sodium hydroxide (special grade reagent) (corresponding to a neutralization degree of acrylic acid of 70 mol %), and then 45 g of a 10 wt % aqueous solution of sodium sulfite was added and uniformly kneaded into the hydrogel with the small meat chopper. The shredded gel after neutralization was dried in a ventilated band dryer {150°C, air speed 2m / sec} to obtain a dried product. The dried product was pulverized in a juicer mixer (Osterizer Blender, manufactured by Oster) to obtain a crosslinked polymer (X-4). This crosslinked polymer (X-4) was adjusted to have a particle size of 150 to 300 μm using sieves with openings of 150 and 300 μm, thereby obtaining a crosslinked polymer (A-4). The volume average particle size of the crosslinked polymer (A-4) was measured with a particle analyzer (CAMSIZER XT, manufactured by Retsch) and found to be 222 μm. The absorption capacity of physiological saline was 36 g / g.
[0083] <Production Example 5: Production of Crosslinked Polymer (A-5)> The crosslinked polymer (X-4) obtained in Production Example 4 was sieved using sieves with openings of 90 and 150 μm to have a particle size of 90 to 150 μm, thereby obtaining a crosslinked polymer (A-5). The volume average particle size of the crosslinked polymer (A-5) was measured with a particle analyzer (CAMSIZER XT, manufactured by Retsch) and found to be 125 μm. The absorption capacity of physiological saline was 33 g / g.
[0084] <Production Example 6: Production of Crosslinked Polymer (A-6)> The crosslinked polymer (X-4) obtained in Production Example 4 was adjusted to a particle size of 500 to 710 μm using sieves with openings of 500 and 710 μm to obtain a crosslinked polymer (A-6). The volume average particle size of the crosslinked polymer (A-6) was measured with a particle analyzer (Retsch, CAMSIZER XT) and found to be 630 μm. The absorption capacity of physiological saline was 38 g / g.
[0085] <Production Example 7: Production of crosslinked polymer (A-7)> A crosslinked polymer (X-7) was obtained in the same manner as in the production method for the crosslinked polymer (X-1) in Production Example 1, except that the amount of ethylene glycol diglycidyl ether was 6 g (5.2 wt % / acrylic acid). This crosslinked polymer (X-7) was adjusted to have a particle size of 150 to 300 μm using sieves with openings of 150 and 300 μm, thereby obtaining a crosslinked polymer (A-7). The volume average particle size of the crosslinked polymer (A-7) was measured with a particle analyzer (CAMSIZER XT, manufactured by Retsch) and found to be 220 μm. The absorption capacity of physiological saline was 3 g / g.
[0086] <Production Example 8: Production of crosslinked polymer (A-8)> A crosslinked polymer (X-8) was obtained in the same manner as in the production method for the crosslinked polymer (X-1) in Production Example 1, except that the amount of ethylene glycol diglycidyl ether was changed to 0.2 g (0.17 wt % / acrylic acid). This crosslinked polymer (X-8) was adjusted to have a particle size of 150 to 300 μm using sieves with openings of 150 and 300 μm, thereby obtaining a crosslinked polymer (A-8). The volume average particle size of the crosslinked polymer (A-8) was measured with a particle analyzer (CAMSIZER XT, manufactured by Retsch) and found to be 220 μm. The absorption capacity of physiological saline was 100 g / g.
[0087] <Production Example 9: Production of Crosslinked Polymer (A-9)> The crosslinked polymer (X-1) obtained in Production Example 1 was adjusted to a particle size of 100 to 200 μm using sieves with 100 and 200 μm openings to obtain a crosslinked polymer (A-9). The volume average particle size of the crosslinked polymer (A-9) was measured with a particle analyzer (Retsch, CAMSIZER XT) and found to be 150 μm. The absorption capacity of physiological saline was 21 g / g.
[0088] <Production Example 10: Production of Crosslinked Polymer (A-10)> The crosslinked polymer (X-1) obtained in Production Example 1 was sieved using sieves with mesh sizes of 250 and 350 μm to have a particle size of 250 to 350 μm, thereby obtaining a crosslinked polymer (A-10). The volume average particle size of the crosslinked polymer (A-10) was measured with a particle analyzer (CAMSIZER XT, manufactured by Retsch) and found to be 300 μm. The absorption capacity of physiological saline was 24 g / g.
[0089] <Production Example 11: Production of Crosslinked Polymer (A-11)> The crosslinked polymer (X-4) obtained in Production Example 4 was sieved using sieves with mesh sizes of 250 and 350 μm to have a particle size of 250 to 350 μm, thereby obtaining a crosslinked polymer (A-11). The volume average particle size of the crosslinked polymer (A-11) was measured with a particle analyzer (CAMSIZER XT, manufactured by Retsch) and found to be 288 μm. The absorption capacity of physiological saline was 34 g / g.
[0090] <Production Example 12: Production of crosslinked polymer (B-1-1)> 28 g of 50 wt% potassium carbonate aqueous solution was sprayed from a spray nozzle to 50 g of the crosslinked polymer (A-1), mixed uniformly, heated at 130°C for 30 minutes, and cooled to room temperature to obtain the crosslinked polymer (B-1-1). The pH of the physiological saline solution of the crosslinked polymer (B-1-1) was 7.5.
[0091] <Production Example 13: Production of crosslinked polymer (B-1-2)> A crosslinked polymer (B-1-2) was obtained in the same manner as in Production Example 12, except that the amount of the 50 wt% potassium carbonate aqueous solution was changed to 20 g. The pH measurement result of a physiological saline solution of the crosslinked polymer (B-1-2) was 7.2.
[0092] <Production Example 14: Production of crosslinked polymer (B-1-3)> A crosslinked polymer (B-1-3) was obtained in the same manner as in Production Example 12, except that the amount of the 50 wt% potassium carbonate aqueous solution was changed to 32 g. The pH measurement result of a physiological saline solution of the crosslinked polymer (B-1-3) was 7.9.
[0093] <Production Example 15: Production of crosslinked polymer (B-1-4)> A crosslinked polymer (B-1-4) was obtained in the same manner as in Production Example 12, except that the amount of the 50 wt% potassium carbonate aqueous solution was changed to 25 g. The pH measurement result of a physiological saline solution of the crosslinked polymer (B-1-4) was 7.3.
[0094] <Production Example 16: Production of crosslinked polymer (B-2-1)> A crosslinked polymer (B-2-1) was obtained in the same manner as in Production Example 12, except that the crosslinked polymer was changed from (A-1) to (A-2) in Production Example 12. The pH measurement result of a physiological saline solution of the crosslinked polymer (B-2-1) was 7.4.
[0095] <Production Example 17: Production of crosslinked polymer (B-3-1)> A crosslinked polymer (B-3-1) was obtained in the same manner as in Production Example 13, except that the crosslinked polymer was changed from (A-1) to (A-3) in Production Example 13. The pH measurement result of a physiological saline solution of the crosslinked polymer (B-3-1) was 7.1.
[0096] <Production Example 18: Crosslinked polymer (B- 4 - 1 ) Manufacturing> The same procedure as in Production Example 12 was repeated except that the crosslinked polymer was changed from (A-1) to (A-4) and 12.5 g of 48 wt % sodium hydroxide was used instead of 28 g of 50 wt % potassium carbonate aqueous solution in Production Example 12 to obtain a crosslinked polymer (B-4-1). The pH measurement result of a physiological saline solution of the crosslinked polymer (B-4-1) was 7.5.
[0097] <Production Example 19: Production of crosslinked polymer (B-5-1)> The same procedure as in Production Example 12 was carried out except that the crosslinked polymer was changed from (A-1) to (A-5) and 12.5 g of 48 wt % sodium hydroxide was used instead of 28 g of 50 wt % potassium carbonate aqueous solution in Production Example 12, to obtain a crosslinked polymer (B-5-1). The pH measurement result of a physiological saline solution of the crosslinked polymer (B-5-1) was 7.4.
[0098] <Production Example 20: Production of crosslinked polymer (B-6-1)> The same procedure as in Production Example 12 was repeated except that the crosslinked polymer was changed from (A-1) to (A-6) and 15.6 g of 48 wt % sodium hydroxide was used instead of 28 g of 50 wt % potassium carbonate aqueous solution in Production Example 12 to obtain a crosslinked polymer (B-6-1). The pH measurement result of a physiological saline solution of the crosslinked polymer (B-6-1) was 7.9.
[0099] <Production Example 21: Production of crosslinked polymer (B-7-1)> A crosslinked polymer (B-7-1) was obtained in the same manner as in Production Example 12, except that the crosslinked polymer was changed from (A-1) to (A-7) in Production Example 12. The pH measurement result of a physiological saline solution of the crosslinked polymer (B-7-1) was 7.4.
[0100] <Production Example 22: Production of crosslinked polymer (B-8-1)> A crosslinked polymer (B-8-1) was obtained in the same manner as in Production Example 12, except that the crosslinked polymer was changed from (A-1) to (A-8) in Production Example 12. The pH measurement result of a physiological saline solution of the crosslinked polymer (B-8-1) was 7.4.
[0101] <Production Example 23: Production of crosslinked polymer (B-9-1)> A crosslinked polymer (B-9-1) was obtained in the same manner as in Production Example 12, except that the crosslinked polymer was changed from (A-1) to (A-9) in Production Example 12. The pH measurement result of a physiological saline solution of the crosslinked polymer (B-9-1) was 7.4.
[0102] <Production Example 24: Production of crosslinked polymer (B-10-1)> A crosslinked polymer (B-10-1) was obtained in the same manner as in Production Example 12, except that the crosslinked polymer was changed from (A-1) to (A-10) in Production Example 12. The pH measurement result of a physiological saline solution of the crosslinked polymer (B-10-1) was 7.4.
[0103] <Production Example 25: Production of crosslinked polymer (B-11-1)> A crosslinked polymer (B-11-1) was obtained in the same manner as in Production Example 12, except that the crosslinked polymer was changed from (A-1) to (A-11) in Production Example 12. The pH measurement result of a physiological saline solution of the crosslinked polymer (B-11-1) was 7.4.
[0104] <Example 1: Production of crosslinked polymer (C-1-1-a)> 2 g of a 5 wt% lecithin (derived from soybeans, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) cyclohexane solution was added dropwise to 10 g of the crosslinked polymer (B-1-1) using a dropper, mixed uniformly, heated at 130°C for 30 minutes, and cooled to room temperature to obtain the crosslinked polymer (C-1-1-a). The volume average particle size of the crosslinked polymer (C-1-1-a) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 220 μm. The absorption capacity of physiological saline was 22 g / g. The pH of the physiological saline solution was measured and found to be 7.4.
[0105] <Example 2: Production of crosslinked polymer (C-1-2-a)> The same procedure as in Example 1 was carried out, except that the crosslinked polymer in Example 1 was changed from (B-1-1) to (B-1-2), to obtain a crosslinked polymer (C-1-2-a). The volume average particle size of the crosslinked polymer (C-1-2-a) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 218 μm. The absorption capacity of physiological saline was 23 g / g. The pH of the physiological saline solution was measured to be 7.1.
[0106] <Example 3: Production of crosslinked polymer (C-1-3-a)> The same procedure as in Example 1 was carried out, except that the crosslinked polymer in Example 1 was changed from (B-1-1) to (B-1-3), to obtain a crosslinked polymer (C-1-3-a). The volume average particle size of the crosslinked polymer (C-1-3-a) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 218 μm. The absorption capacity of physiological saline was 19 g / g. The pH of the physiological saline solution was measured and found to be 7.9.
[0107] <Example 4: Production of crosslinked polymer (C-1-4-a)> The same procedure as in Example 1 was carried out, except that the crosslinked polymer in Example 1 was changed from (B-1-1) to (B-1-4), to obtain a crosslinked polymer (C-1-4-a). The volume average particle size of the crosslinked polymer (C-1-4-a) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 218 μm. The absorption capacity of physiological saline was 22 g / g. The pH of the physiological saline solution was measured and found to be 7.2.
[0108] <Example 5: Production of crosslinked polymer (C-2-1-a)> In Example 1, the crosslinked polymer was changed from (B-1-1) to (B-2-1), and the dripping weight of the 5 wt% lecithin (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., derived from soybeans) cyclohexane solution was changed to 3 g. The same procedure as in Example 1 was carried out to obtain a crosslinked polymer (C-2-1-a). The volume average particle size of the crosslinked polymer (C-2-1-a) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 201 μm. The absorption capacity of physiological saline was 11 g / g. The pH of the physiological saline solution was measured and found to be 7.4.
[0109] <Example 6: Production of crosslinked polymer (C-2-1-b)> In Example 1, the crosslinked polymer was changed from (B-1-1) to (B-2-1), and 1 g of 5 wt % BIGCHAP (Dojindo Chemical Laboratories, N,N-bis(3-D-gluconamidopropyl)cholamide) cyclohexane solution was used instead of 2 g of 5 wt % lecithin (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., derived from soybeans) cyclohexane solution. Except for this, the same procedure as in Example 1 was carried out to obtain crosslinked polymer (C-2-1-b). The volume average particle size of the crosslinked polymer (C-2-1-b) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 207 μm. The absorption capacity of physiological saline was 11 g / g. The pH of the physiological saline solution was measured and found to be 7.4.
[0110] <Example 7: Production of crosslinked polymer (C-3-1-c)> In Example 1, the crosslinked polymer was changed from (B-1-1) to (B-3-1), and 1 g of 5 wt % hexadecyltrimethylammonium chloride (FUJIFILM Wako Pure Chemical Industries, Ltd., HDTMA-Cl) cyclohexane solution was used instead of 2 g of 5 wt % lecithin (FUJIFILM Wako Pure Chemical Industries, Ltd., derived from soybeans) cyclohexane solution. The same procedure as in Example 1 was carried out to obtain a crosslinked polymer (C-3-1-c). The volume average particle size of the crosslinked polymer (C-3-1-c) was measured with a particle analyzer (Retsch, CAMSIZER XT) and found to be 420 μm. The absorption capacity of physiological saline was 32 g / g. The pH of the physiological saline solution was measured and found to be 7.0.
[0111] <Example 8: Production of crosslinked polymer (C-4-1-d)> In Example 1, the crosslinked polymer was changed from (B-1-1) to (B-4-1), and 2 g of 5 wt % lecithin (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd., derived from soybeans) cyclohexane solution was replaced with 2 g of 5 wt % CHAPS (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd., 3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate) cyclohexane solution. The same procedure as in Example 1 was repeated to obtain crosslinked polymer (C-4-1-d). The volume average particle size of the crosslinked polymer (C-4-1-d) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 222 μm. The absorption capacity of physiological saline was 32 g / g. The pH of the physiological saline solution was measured to be 7.0.
[0112] <Example 9: Production of crosslinked polymer (C-4-1-e)> In Example 1, the crosslinked polymer was changed from (B-1-1) to (B-4-1), and 2 g of 5 wt % lauryl alcohol (manufactured by Tokyo Chemical Industry Co., Ltd.) cyclohexane solution was used instead of 2 g of 5 wt % lecithin (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., derived from soybeans) cyclohexane solution. Except for this, the same procedure as in Example 1 was carried out to obtain a crosslinked polymer (C-4-1-e). The volume average particle size of the crosslinked polymer (C-4-1-e) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 228 μm. The absorption capacity of physiological saline was 28 g / g. The pH of the physiological saline solution was measured to be 7.4.
[0113] <Example 10: Production of crosslinked polymer (C-5-1-d)> In Example 1, the crosslinked polymer was changed from (B-1-1) to (B-5-1), and 3 g of 5 wt % CHAPS (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.) cyclohexane solution was used instead of 2 g of 5 wt % lecithin (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd., derived from soybeans) cyclohexane solution. The same procedure as in Example 1 was carried out to obtain a crosslinked polymer (C-5-1-d). The volume average particle size of the crosslinked polymer (C-5-1-d) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 133 μm. The absorption capacity of physiological saline was 30 g / g. The pH of the physiological saline solution was measured and found to be 7.4.
[0114] <Example 11: Production of crosslinked polymer (C-6-1-d)> In Example 1, the crosslinked polymer was changed from (B-1-1) to (B-6-1), and 2 g of 5 wt % lecithin (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd., derived from soybeans) cyclohexane solution was replaced with 2 g of 5 wt % CHAPS (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.) cyclohexane solution, and the same procedure as in Example 1 was carried out to obtain a crosslinked polymer (C-6-1-d). The volume average particle size of the crosslinked polymer (C-6-1-d) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 630 μm. The absorption capacity of physiological saline was 33 g / g. The pH of the physiological saline solution was measured and found to be 7.8.
[0115] <Example 12: Production of crosslinked polymer (C-4-0-a)> The same procedure as in Example 1 was carried out, except that the crosslinked polymer in Example 1 was changed from (B-1-1) to (A-1), to obtain a crosslinked polymer (C-4-0-a). The volume average particle size of the crosslinked polymer (C-4-0-a) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 230 μm. The absorption capacity of physiological saline was 25 g / g. The pH of the physiological saline solution was measured and found to be 6.1.
[0116] <Example 13: Production of crosslinked polymer (C-7-1-a)> The same procedure as in Example 1 was carried out, except that the crosslinked polymer in Example 1 was changed from (B-1-1) to (B-7-1), to obtain a crosslinked polymer (C-7-1-a). The volume average particle size of the crosslinked polymer (C-7-1-a) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 220 μm. The absorption capacity of physiological saline was 3 g / g. The pH of the physiological saline solution was measured and found to be 7.4.
[0117] <Example 14: Production of crosslinked polymer (C-8-1-a)> The same procedure as in Example 1 was carried out, except that the crosslinked polymer in Example 1 was changed from (B-1-1) to (B-8-1), to obtain a crosslinked polymer (C-8-1-a). The volume average particle size of the crosslinked polymer (C-8-1-a) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 220 μm. The absorption capacity of physiological saline was 100 g / g. The pH of the physiological saline solution was measured and found to be 7.4.
[0118] <Example 15: Production of crosslinked polymer (C-9-1-a)> The same procedure as in Example 1 was carried out, except that the crosslinked polymer in Example 1 was changed from (B-1-1) to (B-9-1), to obtain a crosslinked polymer (C-9-1-a). The volume average particle size of the crosslinked polymer (C-9-1-a) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 155 μm. The absorption capacity of physiological saline was 21 g / g. The pH of the physiological saline solution was measured and found to be 7.4.
[0119] <Example 16: Production of crosslinked polymer (C-10-1-a)> The same procedure as in Example 1 was carried out, except that the crosslinked polymer in Example 1 was changed from (B-1-1) to (B-10-1), to obtain a crosslinked polymer (C-10-1-a). The volume average particle size of the crosslinked polymer (C-10-1-a) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 297 μm. The absorption capacity of physiological saline was 22 g / g. The pH of the physiological saline solution was measured and found to be 7.4.
[0120] <Example 17: Production of crosslinked polymer (C-1-1-a2)> In Example 1, the same procedure as in Example 1 was carried out except that 1 g of a 5 wt% lecithin (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., derived from soybeans) cyclohexane solution was used instead of 2 g of a 5 wt% lecithin (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., derived from soybeans) cyclohexane solution, to obtain a crosslinked polymer (C-10-1-a2). The volume average particle size of the crosslinked polymer (C-10-1-a2) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 222 μm. The absorption capacity of physiological saline was 22 g / g. The pH of the physiological saline solution was measured and found to be 7.4.
[0121] <Example 18: Production of crosslinked polymer (C-1-1-a3)> The procedure of Example 1 was repeated except that 4 g of a 20 wt % lecithin (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., derived from soybeans) cyclohexane solution was used instead of 2 g of a 5 wt % lecithin (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., derived from soybeans) cyclohexane solution, to obtain a crosslinked polymer (C-1-1-a3). The volume average particle size of the crosslinked polymer (C-1-1-a3) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 231 μm. The absorption capacity of physiological saline was 23 g / g. The pH of the physiological saline solution was measured and found to be 7.4.
[0122] <Example 19: Production of crosslinked polymer (C-11-1-g)> In Example 1, the crosslinked polymer was changed from (B-1-1) to (B-11-1), and 2 g of a 5 wt % polylysine (number average molecular weight: 4700) cyclohexane solution was used instead of 2 g of a 5 wt % lecithin (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd., derived from soybeans) cyclohexane solution. Except for this, the same procedure as in Example 1 was carried out to obtain a crosslinked polymer (C-11-1-g). The volume average particle size of the crosslinked polymer (C-11-1-g) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 302 μm. The absorption capacity of physiological saline was 30 g / g. The pH of the physiological saline solution was measured to be 7.9.
[0123] <Example 20: Production of crosslinked polymer (C-11-1-h)> In Example 1, the crosslinked polymer was changed from (B-1-1) to (B-11-1), and 2 g of a 0.5 wt % polyethyleneimine (number average molecular weight: 600) cyclohexane solution was used instead of 2 g of a 5 wt % lecithin (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd., derived from soybeans) cyclohexane solution. Except for this, the same procedure as in Example 1 was carried out to obtain a crosslinked polymer (C-11-1-h). The volume average particle size of the crosslinked polymer (C-11-1-h) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 288 μm. The absorption capacity of physiological saline was 28 g / g. The pH of the physiological saline solution was measured to be 7.8.
[0124] <Example 21: Production of crosslinked polymer (C-4-1-f)> In Example 1, the crosslinked polymer was changed from (B-1-1) to (B-4-1), and 2 g of 5 wt % triethanolamine (manufactured by Tokyo Chemical Industry Co., Ltd.) ethanol solution was used instead of 2 g of 5 wt % lecithin (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., derived from soybeans) cyclohexane solution. Except for this, the same procedure as in Example 1 was carried out to obtain crosslinked polymer (C-4-1-f). The volume average particle size of the crosslinked polymer (C-4-1-f) was measured using a particle analyzer (Retsch, CAMSIZER XT) and found to be 241 μm. The absorption capacity of physiological saline was 27 g / g. The pH of the physiological saline solution was measured to be 7.5.
[0125] For the crosslinked polymer (C) produced in each Example, 1 g of the polymer was placed on a petri dish, covered with filter paper, and dried by heating in a circulating air dryer for 60 minutes at 130° C., after which the weight of the residue was measured. The weight ratio after heating to the weight of the crosslinked polymer (C) before heating is shown in Tables 1 to 4 (100-loss on drying (%), where loss on drying (%) means the weight loss ratio during heating to the weight of the polymer (C) before heating).
[0126] <Test example: Recovery of extracellular vesicles using cross-linked polymer> Using the crosslinked polymers produced in Examples 1 to 21 and the following comparative crosslinked polymers, separation and recovery of extracellular vesicles (exosomes) was carried out by the following method, and the recovery amount and degree of purification of the extracellular vesicles were evaluated. In Comparative Example 1, the crosslinked polymer (A-1) obtained in Production Example 1 was used as a crosslinked polymer for comparison. In Comparative Example 2, the crosslinked polymer (B-1-1) obtained in Production Example 12 was used as a crosslinked polymer for comparison. In Comparative Example 3, no crosslinked polymer was added.
[0127] 1 mL of each sample was centrifuged at 1200×g for 10 minutes, and the supernatant from which debris had been removed was collected. 40 mg of crosslinked polymer was added to a 1.5 mL microtube, followed by 1 mL of the supernatant from which debris had been removed, and the tube was left to stand at 25°C for 30 minutes. The supernatant was then discarded, and 0.5 mL of physiological saline (salt concentration 0.9% by weight) was added to the resulting gel, which was then stirred by pipetting, and the supernatant was discarded. This washing procedure was repeated three times. Next, 70 mg of salt was added and the mixture was left to stand for 30 minutes at 25° C. The free liquid was then collected using a pipette, and the collected liquid was sealed in a dialysis tube (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., dialysis membrane size 20, MWCO: 14000) and desalted at 25° C. for 2 hours to collect extracellular vesicles. The weight of the recovered liquid, the amount of exosomes recovered per 1 mL of sample, and the amount of albumin recovered per 1 mL of sample were as shown in Tables 1 to 4. The degree of purification was calculated by the following method. [Purity] = [Exosome recovery amount per 1 mL of sample] / [Albumin recovery amount per 1 mL of sample] The amount of exosomes recovered was measured using an ELISA kit [Cosmo Bio Co., Ltd., CD9 / CD63 Exosome ELISA Kit, Human]. The amount of albumin recovered was measured using an ELISA kit [Proteintech, Human Albumin ELISA Kit].
[0128] For further comparison, the conventional ultracentrifugation method was performed, and the weight of the recovered liquid, the amount of exosomes recovered per 1 mL of sample, and the amount and degree of purification of albumin recovered per 1 mL of sample were evaluated in the same manner as above. A 30 mL sample of human urine was subjected to ultracentrifugation to isolate and collect exosomes. Specifically, centrifugation was performed continuously at 4°C as follows. 30 mL of human urine specimen was centrifuged at 1200×g for 10 minutes, the supernatant was collected, and centrifuged at 10000×g for 30 minutes. The supernatant was then collected and centrifuged at 70000×g for 1 hour, and the supernatant was discarded. The precipitated pellet was resuspended in 5 mL of 0.25 M sucrose solution (20 mM HEPES pH 7.2), and the resulting suspension was added to a 40PA tube containing 30 mL of 0.25 M to 2 M sucrose gradient solution (20 mM HEPES pH 7.2), and centrifuged at 100000×g for 20 hours. The liquid in the 40PA tube was sucked up from the bottom, and 2 mL of 8 mL to 12 mL fractions were collected into 5PA tubes containing 3 mL of PBS (-). The collected liquid was centrifuged at 200,000×g for 1 hour, and the precipitated pellet was resuspended in 150 μL of PBS(-) to recover extracellular vesicles.
[0129] The results are shown in Tables 1 to 4. [Table 1]
[0130] [Table 2]
[0131] [Table 3]
[0132] [Table 4] [Industrial Applicability]
[0133] The crosslinked polymer of the present invention can be suitably used for separating a substance having a lipid bilayer from a biological sample. The separation method of the present invention can increase the purity of the separated substance having a lipid bilayer and shorten the operation time, for example, compared with conventional ultracentrifugation methods. In addition, the separation method of the present invention can reduce the number of steps and has excellent reproducibility, compared with conventional ultracentrifugation methods. The separated substance having a lipid bilayer can be used for evaluating the state of the original organism (for example, testing or diagnosis). In addition, the separated substance having a lipid bilayer can be used as a carrier for cell-targeted therapeutic drugs, etc.
Claims
1. A crosslinked polymer for separating a substance having a lipid bilayer from a biological sample, the crosslinked polymer comprising a monomer unit having an acidic group and / or a neutralizing base thereof, and a compound having at least one group selected from the group consisting of a cationic group and a hydroxyl group, the compound being a compound having an optionally substituted alkyl group having 12 to 30 carbon atoms and / or an optionally substituted alkenyl group having 12 to 30 carbon atoms and a cationic group, or a compound having an optionally substituted alicyclic hydrocarbon group having 12 to 30 carbon atoms, a cationic group, and a hydroxyl group, the alicyclic hydrocarbon group being a group having a steroid skeleton, and the cationic group being -N + (R 2 ) 3 (wherein each R 2 is independently a hydrogen atom, or an optionally substituted hydrocarbon group having 1 to 6 carbon atoms).
2. 2. The crosslinked polymer according to claim 1, wherein the alicyclic hydrocarbon group having 12 to 30 carbon atoms is an alicyclic hydrocarbon group having 20 to 30 carbon atoms.
3. 3. The crosslinked polymer according to claim 1, wherein a physiological saline solution containing 0.5% by weight of the crosslinked polymer based on the weight of the physiological saline has a pH of 7 to 8.
4. The crosslinked polymer described in any one of claims 1 to 3, wherein the volume average particle diameter of the crosslinked polymer is 130 to 630 μm.
5. The crosslinked polymer according to any one of claims 1 to 4, wherein the substance having a lipid bilayer is an extracellular vesicle.
6. A method for separating a substance having a lipid bilayer from a biological sample, comprising the following steps (1) and (2): (1) contacting a biological sample with the crosslinked polymer according to any one of claims 1 to 5 to obtain a polymer gel containing a substance having a lipid bilayer; and (2) mixing the polymer gel with a salt and recovering a substance having a lipid bilayer; wherein the salt is a monovalent or divalent metal salt.
7. A kit for separating a substance having a lipid bilayer from a biological sample, comprising the crosslinked polymer according to any one of claims 1 to 5 and a salt, wherein the salt is a monovalent or divalent metal salt.
8. A kit for testing for a disease using extracellular vesicles, comprising the crosslinked polymer of any one of claims 1 to 5 and a salt, wherein the salt is a monovalent or divalent metal salt.
9. An apparatus for separating a substance having a lipid bilayer from a biological sample, comprising means for carrying out the method according to claim 6.
Citation Information
Patent Citations
Water-soluble complexes of membrane proteins-amphiphilic acrylic polymers and their applications in diagnostics
JP2001519836A
Isolation of extracellular vesicles (EVs) from body fluid samples
JP2019518428A
Methods and compositions for the purification or isolation of microvesicles and exosomes
JP2020502067A
Production method for coated particle and column production method
JP2021007915A
JPP2884063B
